| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.4 | 3.7 |
| Profit before tax | 4.7 | -29.8 |
| Net income | 4.2 | -29.8 |
| EPS (diluted, $ a share) | $-0.03 | $-0.13 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -61.0% |
|---|
10-Q filed with the SEC, NYSE: LCTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Lineage Cell Therapeutics, Inc.: key numbers
- Share price
- $0.7951Close, Nov 16
- Market cap
- $201M
- Shares outstanding
- 252.95MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Lineage Cell Therapeutics, Inc.
All →Lineage Cell Therapeutics President and CEO Brian M. Culley Buys $37.1K of Stock
Brian M. Culley, President and CEO, bought 40,500 shares of Lineage Cell Therapeutics, Inc. at $0.916 a share, worth $37.1K in total on Nov 16, 2026. Shares held after the trade: 296,016 (+15.9%).
- Value
- $37.1K
- Shares
- 40,500
- Price
- $0.9160
- Role
- President and CEO
- Holding change
- +15.9%
- Trade date
- Nov 16, 2026
Lineage Cell Therapeutics Signs $2.4M M&A Deal with NeuroAirmid Therapeutics, Inc.
Lineage Cell Therapeutics acquired NeuroAirmid Therapeutics, Inc., adding a clinical-stage neural cell therapy program (HUNT1) for Huntington’s Disease to its pipeline. The deal involved a $2.4 million upfront cash payment and the assumption of a co-funding obligation for an ongoing Phase 1b/2a clinical study supported by CIRM.
- Value
- $2.4M
- Counterparty
- NeuroAirmid Therapeutics, Inc.
“Today, we closed the acquisition of NeuroAirmid Therapeutics adding HUNT1, a third clinical-stage asset to our development pipeline. HUNT1 is a pluripotent stem cell derived, clinical-stage neural cell therapy program, with the potential to validate a new cell-based treatment modality for Huntington’s Disease.”
Brian M. Culley, Lineage CEO
“This transaction reflects the disciplined approach to capital allocation and strategic fit that we believe our investors have come to expect from Lineage. HUNT1 was created on the same proprietary cell line that Lineage uses and is compatible with its AlloSCOPE “5D” technology, providing us with a head start on our planned contributions.”
Brian M. Culley, Lineage CEO